Beilu Pharmaceutical: Announcement on Adjusting the Amount of Raised Funds to be Invested in Investment Projects with Raised Funds
Stock code: 300016 Stock abbreviation: Beilu Pharmaceutical Announcement number: 2026-042
Beijing Beilu Pharmaceutical Co., Ltd.
Announcement on Adjusting the Amount of Raised Funds to be Invested in Investment Projects with Raised Funds
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Beijing Beilu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Beilu Pharmaceutical") held the 11th meeting of the ninth board of directors on May 18, 2026, and reviewed and approved the "Proposal on Adjusting the Amount of Raised Funds to be Invested in Investment Projects with Raised Funds", and agreed that the company will adjust the amount of funds to be invested in investment projects with raised funds (hereinafter referred to as "Raised Investment Projects") based on the actual use of raised funds. The relevant information is now announced as follows:
1. Basic situation of raised funds
With the approval of the China Securities Regulatory Commission's "Reply on the Registration of Beijing Beilu Pharmaceutical Co., Ltd.'s Issuance of Stocks to Specific Targets" (CSRC Permit [2026] No. 827), the company issued 18,816,568 RMB ordinary shares (A shares) to specific targets in 2025 through a simplified procedure, with a face value of RMB 1 per share, an issue price of RMB 8.45 per share, and a total amount of funds raised of RMB 8.45 per share. 158,999,999.60 yuan. After deducting the sponsor and underwriting fees and other issuance expenses of 3,732,040.17 yuan (excluding value-added tax), the actual net amount of funds raised was RMB 155,267,959.43.
The above-mentioned funds have been remitted to the company's special fund-raising account on April 27, 2026. The status has been verified by Grant Thornton Accounting Firm (Special General Partnership), and a "Capital Verification Report" (Grant Thornton Yanzi (2026) No. 110C000111) was issued on April 28, 2026. The company has stored the funds raised this time in a special account. The company and its wholly-owned subsidiary Luzhibao Pharmaceutical Co., Ltd. have opened special accounts for raised funds respectively and signed a "Tripartite Supervision Agreement for Raised Funds" with the account-opening bank and the sponsor.
2. Adjustments to the amount of funds to be invested in the investment project
In view that the actual net amount of funds raised by the company is lower than the amount of funds planned to be used for the investment project in the "Beijing Beilu Pharmaceutical Co., Ltd. 2025 Prospectus for Issuing Stocks to Specific Targets with Simple Procedures (Registration Draft)", based on the actual net amount of funds raised and the company's actual operating needs, in order to ensure the smooth implementation of the investment project and without changing the use of the funds raised, the company plans to adjust the amount of funds planned to be invested in the investment project. The specific adjustments are as follows:
Unit: RMB 10,000 Planned investment before adjustment Planned investment after adjustment Serial number Project name Total project investment
Raising funds Raising funds Lu Zhibao chemical production workshop and intelligent
1 39,340.68 15,900.00 15,526.80 Comprehensive warehouse project
Total 39,340.68 15,900.00 15,526.80
After the company adjusts the amount of funds it intends to invest in the fund-raising projects, the company will raise the shortfall in the investment amount by itself.
3. The impact of this adjustment on the amount of funds to be invested in the investment project on the company
The company's adjustment of the amount of funds to be invested in the raised investment project this time is a prudent decision based on the actual receipt of raised funds and the company's actual operating needs. It will not affect the normal progress of the investment plan of raised funds. There will be no change or disguised change in the use of raised funds or damage to the interests of shareholders, and it will not have an adverse impact on the company's operating conditions. The company will strictly abide by the requirements on the use of raised funds in relevant laws and regulations, strengthen the management and supervision of the construction of raised investment projects and the use of raised funds, improve the efficiency of the use of raised funds, and protect the interests of the company and all shareholders.
4. Implementation review procedures and related opinions
(1) Review status of the board of directors
On May 18, 2026, the company held the 11th meeting of the ninth board of directors and reviewed and approved the "Proposal on Adjusting the Amount of Raised Funds to be Invested in Investment Projects with Raised Funds". The Board of Directors agreed that the company would adjust the amount of funds to be invested in the raised investment projects based on the actual net amount of funds raised and the actual situation of the raised investment projects.
(2) Sponsor’s verification opinions
After verification, the sponsor believes that: the company's adjustment of the amount of funds to be invested in the fundraising project has been reviewed and approved by the company's board of directors, and the necessary approval procedures have been performed, and is in compliance with the "Supervision Rules for Funds Raised by Listed Companies", "Shenzhen Stock Exchange GEM Stock Listing Rules" and "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 2 - Standardized Operation of GEM Listed Companies" and other relevant regulations and the company's fund-raising management methods. The company's adjustment of the amount of funds to be invested in the raised investment project does not change the purpose of the raised funds in any disguised manner. It will not affect the construction of the raised funds projects and the use of raised funds, nor will it have an adverse impact on the company's operating activities, and will not harm the interests of the company and shareholders.
In summary, the sponsor has no objection to the company’s adjustment of the amount of funds to be invested in the investment project.
5. Documents for reference
Resolution of the 11th meeting of the 9th Board of Directors;
CITIC Securities Co., Ltd.’s verification opinions on Beijing Beilu Pharmaceutical Co., Ltd.’s adjustment of the amount of funds to be invested in the fundraising project.
Announcement is hereby made.
Beijing Beilu Pharmaceutical Co., Ltd. Board of Directors
May 18, 2026